UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): February 14, 2017
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-33357 | 65-0643773 | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 2 Snunit Street | ||
| Science Park, POB 455 | ||
| Carmiel, Israel | 20100 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code +972-4-988-9488
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.08 Shareholder Director Nominations
The Board of Directors of Protalix BioTherapeutics, Inc. (the “Company”) has approved the record date for the Company’s 2017 Annual Meeting of Stockholders (the “Annual Meeting”) to be held on or about April 10, 2017. Holders of the Company’s common stock at the close of business on March 15, 2017, the record date, will be entitled to receive notice of, and to vote at, the Annual Meeting. The final date and time of the meeting will be announced in the proxy statement to be filed and distributed by the Company in connection with the Annual Meeting.
In order for a proposal to be considered timely, it must be received by the Company on or prior to March 2, 2017 at its principal executive offices at 2 Snunit Street, Science Park, P.O. Box 455, Carmiel 20100, Israel. Proposals should be directed to the attention of the Secretary.
The Company plans to file with the Securities and Exchange Commission (the “SEC”), and mail to its Stockholders a proxy statement in connection with the Annual Meeting, and advises its stockholders to read the proxy statement relating to the Annual Meeting when it becomes available, as it will contain important information. Stockholders may obtain a free copy of the proxy statement and any other relevant documents (when available) that the Company files with the SEC via the SEC’s web site at www.sec.gov. The proxy statement and these other documents, when available, may also be obtained free of charge from the Company by directing a request to the Company at 2 Snunit Street, Science Park, P.O. Box 455, Carmiel 20100, Israel, Attention: Secretary.
The Company, its directors and named executive officers may be deemed to be participants in the solicitation of the Company’s stockholders in connection with the Annual Meeting. Stockholders will be able to obtain information regarding the names, affiliations and interests of such individuals in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, and in the other filings by the Company with the SEC.
Item 9.01. Financial Statements and Exhibits
| (d) | Exhibits |
| 99.1 | Press release dated February 14, 2017. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PROTALIX BIOTHERAPEUTICS, INC. | ||||
| Date: February 14, 2017 | By: | /s/ Moshe Manor | ||
| Name: | Moshe Manor | |||
| Title: | President and Chief Executive Officer | |||
Exhibit 99.1
Protalix BioTherapeutics Announces Record
Date
for the 2017 Annual Meeting of Stockholders
CARMIEL, Israel, February 14, 2017 /GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE MKT:PLX, TASE:PLX), announced today that its board of directors approved the record date for the Company’s 2017 Annual Meeting of Stockholders (the “Annual Meeting”) to be held on or about April 10, 2017. Holders of the Company’s common stock at the close of business on March 15, 2017, the record date, will be entitled to receive notice of, and to vote at, the Annual Meeting.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix’s development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others.
Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes, and are valid only as of the date hereof. We disclaim any obligation to update this information, except as may be required by law.
Investor Contact
Marcy Nanus
The Trout Group, LLC
646-378-2927
mnanus@troutgroup.com
Source: Protalix BioTherapeutics, Inc.